Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients

Diabetes Care. 1995 Nov;18(11):1487-90. doi: 10.2337/diacare.18.11.1487.

Abstract

Objective: To measure the effects of cyclosporin A (CyA) with no insulin therapy on glucose tolerance and beta-cell function in the preclinical phase of insulin-dependent diabetes mellitus (IDDM).

Research design and methods: beta-cell responses to the intravenous glucose tolerance test (IVGTT), hyperglycemic clamp, intravenous arginine, and intravenous glucagon were evaluated before and after a 6-month course of CyA in seven patients (mean age 19.6 years) with asymptomatic IDDM.

Results: Initial insulin secretory responses were severely decreased when the patients were compared with eight healthy control subjects: IVGTT (1 + 3 min): 106 +/- 16 vs. 884 +/- 190 pmol/l (P < 0.001); hyperglycemic clamp: 102 +/- 16 vs. 310 +/- 42 pmol/l (P < 0.001); intravenous arginine: 346 +/- 72 vs. 1104 +/- 168 pmol/l (P < 0.01); and intravenous glucagon: 170 +/- 37 vs. 247 +/- 35 pmol/l (NS). The beta-cell responses remained markedly abnormal after 6 months of CyA, although the response to intravenous glucose and oral glucose tolerance tests improved in three subjects. All the patients became insulin-dependent after 5-36 months.

Conclusions: CyA alone is not a suitable treatment for asymptomatic IDDM. Earlier identification of subjects with substantial beta-cell secretory capacity and newer nontoxic intervention strategies are required for the prevention of IDDM.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Arginine / pharmacology
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • C-Peptide / blood
  • Cyclosporine / therapeutic use*
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / genetics
  • Diabetes Mellitus, Type 1 / physiopathology
  • Female
  • Follow-Up Studies
  • Glucagon / pharmacology
  • Glucose Clamp Technique
  • Glucose Tolerance Test
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Insulin / metabolism*
  • Insulin / therapeutic use*
  • Insulin Secretion
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / physiopathology
  • Male
  • Reference Values

Substances

  • Blood Glucose
  • C-Peptide
  • Hypoglycemic Agents
  • Immunosuppressive Agents
  • Insulin
  • Cyclosporine
  • Glucagon
  • Arginine